Vyepti 100mg/1ml Vial Single Dose is administered by intravenous infusion, helps prevent migraine attacks and reduces the number of migraine days in adults who experience migraines at least 4 days per month.
Vyepti contains the active ingredient eptinezumab, which blocks the activity of calcitonin gene-related peptide (CGRP) — a molecule found at elevated levels in people with migraine.
Vyepti is used for the prevention of migraine in adults who experience migraine symptoms at least 4 days per month.
It helps reduce the number of migraine days and improve quality of life. Its preventive effect begins the day after administration.
Vyepti is administered by intravenous infusion over 30 minutes by a healthcare professional.
The recommended dose is 100 mg every 12 weeks.
Some patients may require a 300 mg dose every 12 weeks.
Possible side effects include:
Sore throat
Nasal congestion
Fatigue
Vyepti should not be used in:
Patients with hypersensitivity to its ingredients
Children and adolescents under 18 years of age
Use with caution and consult a doctor before using Vyepti, especially in cases of:
Pregnancy and breastfeeding
Cardiovascular diseases
Keep out of the reach of children.
Store in a refrigerator at 2–8°C.
Do not freeze.
If removed from the refrigerator, it may be kept at room temperature (25°C) in its original carton for up to 7 days; discard if not used afterward.
After dilution, the solution may be stored at room temperature (25°C) or in a refrigerator (2–8°C) and must be used within 8 hours.
Store in the original package, protected from light.